Effect of IV Ketorolac to prevention post ERCP pancreatitis

Comparison of efficacy IV Ketorolac and Indomethacin to prevention post ERCP pancreatitis and hyperamylasemia in pateints under going ERCP

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190420043330N1

Enrollment

Registered

2020-03-30

Start date

2019-05-15

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post ERCP pancreatitis. Acute pancreatitis

Interventions

Intervention 1: The standard treatment was ridge-ralctate serum hydration at a rate of 1.5cc / kg / h during ERCP and eight hours after receiving indomethacin suppository rectal immediately after ERCP

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Indication of ERCP

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Rate of Acute Pancreatitis Post Ercp. Timepoint: At intervals 2, 12 and 24 hours after ERCP, blood samples are taken to check serum amylase and lipase. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Hosseini

Qazvin University of Medical Sciences

n.hosseini@qums.ac.ir+98 13 4233 0086

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026